Troesch Myriam, Jalbert Emilie, Canobio Sophie, Boulassel M Rachid, Routy Jean-Pierre, Bernard Nicole F, Bruneau Julie, Lapointe Normand, Boucher Marc, Soudeyns Hugo
Unité d'Immunopathologie Virale, Centre de Recherche, Hôpital Sainte-Justine, Montreal, Quebec, Canada.
AIDS. 2005 May 20;19(8):775-84. doi: 10.1097/01.aids.0000168971.57681.6e.
Hepatitis C virus (HCV) F protein is encoded in an alternate reading frame overlapping the core protein region. Its precise sequence, biological function and mode of expression are currently unclear. This study was conducted to examine the prevalence and characteristics of host humoral and cell-mediated immune responses directed against F protein in patients co-infected with HCV and HIV-1.
Mutations were introduced to allow the expression of HCV-1a F protein in the absence of core. This recombinant and a truncated form lacking the first 11 amino acid residues shared with core were expressed in Escherichia coli, and their amino acid sequences were verified by mass spectrometry. Vaccinia-F protein recombinants were used to test F protein-specific cytotoxic T lymphocyte (CTL) activity. The binding of F protein-derived peptides to HLA-A*0201 was studied to identify putative CTL epitopes.
Sera from 23 of 39 patients infected with various HCV genotypes recognized the truncated form, including 13 of 25 subjects co-infected with HIV-1, indicative of antigenic crossreactivity and consistent with the conservation of F protein coding sequences between HCV genotypes. Crossreactive F protein-specific CTL precursors were detected in nine of 11 HCV-infected subjects, including seven of nine patients co-infected with HCV and HIV-1. Finally, three novel putative HLA-A*0201-restricted CTL epitopes were identified.
These results indicate that patients co-infected with HCV and HIV-1 can mount immunoglobulin and CTL responses directed against HCV F protein that are fully comparable in scope and magnitude with those observed in individuals infected with HCV alone.
丙型肝炎病毒(HCV)F蛋白由与核心蛋白区域重叠的交替阅读框编码。其精确序列、生物学功能和表达模式目前尚不清楚。本研究旨在检测HCV和HIV-1合并感染患者中针对F蛋白的宿主体液免疫和细胞介导免疫反应的流行情况及特征。
引入突变以在无核心蛋白的情况下表达HCV-1a F蛋白。这种重组体和缺少与核心蛋白共享的前11个氨基酸残基的截短形式在大肠杆菌中表达,其氨基酸序列通过质谱法进行验证。痘苗-F蛋白重组体用于检测F蛋白特异性细胞毒性T淋巴细胞(CTL)活性。研究F蛋白衍生肽与HLA-A*0201的结合,以鉴定推定的CTL表位。
39例感染各种HCV基因型的患者中,23例患者的血清识别截短形式,包括25例合并感染HIV-1的患者中的13例,表明存在抗原交叉反应,并且与HCV基因型之间F蛋白编码序列的保守性一致。在11例HCV感染患者中的9例中检测到交叉反应性F蛋白特异性CTL前体,包括9例合并感染HCV和HIV-1的患者中的7例。最后,鉴定出三个新的推定的HLA-A*0201限制性CTL表位。
这些结果表明,HCV和HIV-1合并感染患者可产生针对HCV F蛋白的免疫球蛋白和CTL反应,其范围和强度与单独感染HCV的个体中观察到的完全相当。